Implant-delivery tool

Information

  • Patent Grant
  • 11439833
  • Patent Number
    11,439,833
  • Date Filed
    Tuesday, July 21, 2020
    3 years ago
  • Date Issued
    Tuesday, September 13, 2022
    a year ago
Abstract
Apparatus is provided for facilitating percutaneous delivery of an implant to a target site of a body of a subject. The apparatus includes a delivery tool that includes a needle that defines a lumen through which the implant passes. The needle has a proximal end and a distal end, and defines a triple-grind bevel at the distal end. The triple-grind bevel defines a primary grind and two side-grinds. The side-grinds do not extend to meet each other to define a point at a distal-most part of the needle. Other embodiments are also described.
Description
FIELD OF THE INVENTION

The present invention relates generally to medical devices, and specifically to apparatus and methods for use with percutaneous implants.


BACKGROUND

Neurological disorders affect the nerves, muscles or the brain. Many neurological disorders reduce or eliminate voluntary recruitment of muscles, which may result in loss of ability to perform motor tasks or to maintain systems that depend on muscle activity for their function. Other disorders may cause pain to adjacent tissues.


Neurostimulation is a clinical tool used to treat various neurological disorders, and involves modulation of the nervous system by electrically activating fibers in the body.


SUMMARY OF THE INVENTION

For some applications of the invention, a system is provided comprising an implant, and a delivery tool therefor. The implant has an antenna and at least one electrode. The delivery tool comprises a hollow needle that typically has lateral openings. The delivery tool has discrete states. Typically, in a first state, the implant is entirely housed by the needle, and/or the antenna is disposed proximally from the lateral openings in the needle. Typically, in a second state, a distal portion of the implant is exposed out of the distal end of the needle, and/or the antenna is aligned with the lateral openings. In a third state, the implant is entirely disposed outside of the distal end of the needle. The system (i) facilitates testing of potential implantation sites for the implant, and (ii) increases the safety of advancing implants close to nerve tissue.


For some applications of the invention, the needle defines, at its distal end, a triple-grind bevel that defines (i) a primary grind, and (ii) two side-grinds that do not extend to meet each other to define a point at a distal-most part of the needle. This triple-grind bevel may be used for needles other than that of the delivery tool described herein.


For some applications, the implant defines a recessed portion around which a cuff is disposed, the cuff facilitating anchoring of the implant.


There is further provided, in accordance with an application of the present invention, apparatus for facilitating percutaneous delivery of an implant to a target site of a body of a subject, the implant including an antenna, and the apparatus including:


a delivery tool including a hollow needle that defines lateral openings in a wall of the needle, the hollow needle being configured to house the implant,


the delivery tool being configured to define:

    • a first state, in which the implant is housed by the needle such that the antenna is disposed proximally from the lateral openings,
    • a second state, in which a distal portion of the implant is exposed from a distal end of the needle, and the antenna is aligned with the lateral openings, and
    • a third state, in which the implant is entirely disposed outside of the distal end of the needle.


In an application, in the first state, the entire implant is disposed within the needle.


In an application, in the first state, the entire implant is disposed proximally from the lateral openings.


In an application, in the first state, the distal portion of the implant is aligned with the lateral openings.


In an application, the hollow needle is a hollow metal needle.


In an application, the hollow needle defines a triple-grind bevel at the distal end of the needle, the triple-grind bevel defining:


a primary grind, and


two side-grinds that do not extend to meet each other to define a point at a distal-most part of the needle.


In an application, the apparatus further includes the implant.


In an application:


the implant is an electrostimulator implant, and includes:

    • an implant body, the implant being injectable into tissue of a subject along a longitudinal axis of the implant body;
    • a proximal electrode, and a distal electrode disposed on the implant body distally from the proximal electrode, and


in the second state of the delivery tool, the distal electrode is exposed from the distal end of the needle.


In an application, in the first state of the delivery tool, the proximal electrode and the distal electrode are disposed within the needle.


In an application, the antenna is configured to receive energy wirelessly.


There is further provided, in accordance with an application of the present invention, a method for percutaneously delivering an implant to a target site of a body of a subject, the method including:


inserting into tissue of the subject a hollow needle of a delivery tool, while the delivery tool is in a first state, in which the implant is entirely housed within the needle and no portion of the implant is exposed through the lateral openings in the needle wall;


subsequently, switching the delivery tool to a second state, in which a distal portion of the implant is exposed from a distal end of the needle, and a proximal portion of the implant is at least partially exposed through lateral openings defined by the needle wall; and


subsequently, switching the delivery tool to a third state, in which the implant is entirely disposed outside of the distal end of the needle.


In an application, the method further includes, while the delivery tool is in the second state, advancing the delivery tool and the implant distally within the body of the subject.


There is further provided, in accordance with an application of the present invention, a method for percutaneously delivering an implant through a region of a body of the subject to a target site of the body, the region including a fascia and non-fascia tissue, the method including:


advancing, distally through the fascia, a hollow needle of a delivery tool, while the delivery tool is in a first state in which the implant is entirely housed within the needle;


switching the delivery tool to a second state in which a proximal portion of the implant is housed within the needle, and a distal portion of the implant is exposed from a distal end of the needle; and


while the delivery tool is in the second state, advancing the hollow needle distally through non-fascia tissue.


In an application, the method further includes, prior to advancing the hollow needle distally through the fascia, switching the delivery tool into the first state.


In an application, the method further includes, prior to switching the tool into the first state, advancing the hollow needle distally through non-fascia tissue toward the fascia while the tool is in the second state.


In an application, the method further includes, subsequently to the step of advancing the hollow needle distally through the non-fascia tissue while the delivery tool is in the second state, switching the delivery tool to a third state, in which the implant is entirely disposed outside of the distal end of the needle.


In an application, the method further includes, while the delivery tool is in the third state, releasing the implant from the delivery tool.


There is further provided, in accordance with an application of the present invention, apparatus for facilitating percutaneous delivery of an implant to a target site of a body of a subject, the apparatus including:


a needle including:

    • a distal end; and
    • a proximal end,
    • the needle defining:
      • a lumen configured to facilitate passage of the implant therethrough, and
      • a triple-grind bevel at the distal end of the needle, the triple-grind bevel defining:
        • a primary grind, and
        • two side-grinds that do not extend to meet each other to define a point at a distal-most part of the needle.


In an application, the needle defines lateral openings in a wall of the needle, the openings being proximal from the distal end of the needle.


In application, the needle is a metal needle.


In an application, the two side-grinds converge distally at an angle of 65-85 degrees to each other.


In an application, the primary grind defines an angle of 15-25 degrees with respect to a central longitudinal axis of the needle.


In an application, the side-grinds converge distally, but at the distal-most part of the needle, the side-grinds are spaced apart by 0.1-0.4 mm.


There is further provided, in accordance with an application of the present invention, a method for percutaneously delivering an implant to a target site of a body of a subject, the method including:


inserting the implant into the subject's tissue;


activating the implant to apply a current to the subject's tissue at a first site within the tissue at a first power level;


measuring a response of the subject to the application of the current to the first site at the first power level;


in response to detecting that the subject responded in a given manner to the application of the current to the first site at the first power level, iteratively applying current to the first site at iteratively lower power levels until detecting that, at a second power level, the subject no longer responds, in the given manner, to the application of current to the first site; and


subsequently:

    • moving the implant to one or more further sites within the subject's tissue and applying current to the tissue, at the one or more further sites, at the second power level;
    • measuring a response of the subject to the application of current to the subject's tissue at the one or more further sites; and
    • in response to detecting that the subject responds, in the given manner, to application of the current at the second power level at a given one of the one or more further sites, implanting the implant closer to the given site than to the first site.


In an application:


inserting the implant includes inserting the implant while the implant is at least partly disposed within a hollow needle of a delivery tool,


moving the implant includes moving the implant while the implant is at least partly disposed within the hollow needle, and


activating the implant includes activating the implant while (i) the implant is at least partly disposed within the hollow needle, and (ii) an electrode of the implant is exposed from a distal end of the hollow needle.


In an application, activating the implant includes wirelessly activating the implant while an antenna of the implant is aligned with a lateral opening in a wall of the hollow needle.


In an application, moving the implant includes moving the implant while the electrode of the implant remains exposed from the distal end of the hollow needle.


There is further provided, in accordance with an application of the present invention, apparatus including:


an implant configured to be implanted in tissue of a subject, the implant including:

    • an implant body that includes:
      • at least a first longitudinal portion of the implant body that defines a given outer diameter; and
      • a recessed longitudinal portion of the implant body that is radially recessed with respect to the first longitudinal portion of the implant body, such that an outer diameter of the recessed longitudinal portion is less than the outer diameter of the first longitudinal portion; and
    • a cuff coupled to the implant body around the recessed longitudinal portion of the implant body such that an outer diameter of the cuff does not exceed the outer diameter of the first longitudinal portion,
    • the cuff defining a plurality of holes that are configured to facilitate anchoring of the implant body with respect to the subject's tissue, by facilitating tissue growth into the holes.


In an application, the cuff extends less than 360 degrees around the recessed longitudinal portion.


In an application, each hole of the plurality of holes has a diameter of 200-550 microns.


In an application, the cuff has a thickness of 200-550 microns.


In an application, the implant further includes an antenna, disposed within the recessed longitudinal portion.


In an application, the recessed longitudinal portion does not include a distal end or a proximal end of the implant.


In an application, the cuff includes a resilient material.


In an application, the apparatus further includes a delivery tool that includes a hollow needle through which the implant is slidable, and the outer diameter of the cuff is such that the cuff does not grip the inside of the hollow needle.


In an application, the hollow needle defines a triple-grind bevel at a distal end of the needle, the triple-grind bevel defining:


a primary grind, and


two side-grinds that do not extend to meet each other to define a point at a distal-most part of the needle.


The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-C are schematic illustrations of a system comprising an implant and a delivery tool therefor, in accordance with some applications of the invention;



FIGS. 2A-H are schematic illustrations of a technique for using the delivery tool to implant the implant, in accordance with some applications of the invention;



FIGS. 3A-D are schematic illustrations of a tip of a needle of the delivery tool, in accordance with some applications of the invention; and



FIGS. 4A-C are schematic illustrations of the implant, in accordance with some applications of the invention.





DETAILED DESCRIPTION OF EMBODIMENTS

Reference is made to FIGS. 14-C, 2A-H, 3, and 4A-C, which are schematic illustrations of a system 20 and techniques for using the system, in accordance with some applications of the invention. System 20 comprises an implant 40, and a delivery tool 100 for percutaneous implantation of the implant.


Implant 40 comprises an implant body 42, circuitry 44 and an antenna 46 disposed within the implant body, and at least one electrode 48 (e.g., a proximal electrode 48p and a distal electrode 48d) disposed on the outside of the implant body. Implant 40 has a proximal portion 50p (e.g., a proximal half) that includes a proximal end of the implant, and a distal portion 50d (e.g., a distal half) that includes a distal end of the implant. Typically, at least one of electrodes 48 (e.g., a distal electrode 48d) is disposed at distal portion 50d. Typically, antenna 46 is disposed proximally from that at least one electrode 48. For example, antenna 46 may be disposed proximally from distal portion 50d, such as within proximal portion 50p.


At proximal portion 50p (e.g., at the proximal end) of implant 40, the implant (e.g., implant body 42) defines an implant-coupling 52 that is reversibly couplable to a complementary tool-coupling of tool 100.


Tool 100 comprises a hollow needle 102 at a distal part of the tool, and a control portion 104 at a proximal part of the tool, the control portion typically comprising a handle 106. Needle 102 has a lateral wall that circumscribes a longitudinal axis ax1 of the needle to define a lumen along the longitudinal axis. Needle 102 defines lateral openings 108 (e.g., longitudinal slits) in the lateral wall. Tool 100 is configured to define at least three states, which are shown in FIGS. 1-C, respectively.



FIGS. 1A-C show implant 40 loaded in tool 100. In the first state (FIG. 1A), implant 40 is housed by needle 102 such that antenna 46 is disposed proximally from openings 108. For some applications, in the first state the entire of implant 40 is disposed proximally from openings 108 (i.e., proximally along longitudinal axis ax1 of needle 102). Alternatively, and as shown, some of the implant (e.g., distal portion 50d) is aligned with openings 108 (i.e., disposed at the same part of longitudinal axis ax1 of needle 102), and/or distally from the openings (i.e., distally along the longitudinal axis of needle 102). Typically, and as shown, in the first state, all of electrodes 48 are disposed within needle 102 (i.e., the lumen thereof). For example, and as shown, in the first state, implant 40 may be disposed entirely within needle 102.


In the second state (FIG. 18), distal portion 50d of implant 40 is exposed from the distal end of needle 102, and antenna 46 is aligned with openings 108 (i.e., disposed at the same part of longitudinal axis ax1 of the needle). Typically, in the second state, electrode 48d is exposed from the distal end of needle 102.


In the third state (FIG. 1C), implant 40 is entirely disposed outside of the distal end of needle 102.


Implant 40 is an electrostimulator implant, and drives electrodes 48 to apply current to tissue of the subject in which the implant is implanted. Implant 40 is controlled and/or powered wirelessly, e.g., by transmitting wireless signals from an extracorporeal controller (not shown). Such signals are received by antenna 46. Needle 102 is typically metallic. Openings 108 allow such wireless signals to pass into the lumen of needle 102. Other parts of needle 102 are relatively opaque to such signals. During implantation of implant 40, and before final deployment (i.e., release) of the implant, the implant is activated such that it drives electrodes 48 to apply current to the tissue, in order to determine if its current location within the tissue is an effective location for implanting the implant (e.g., by determining if its desired effect on the subject occurs). The inventors hypothesize that it is advantageous to prevent the operator (e.g., the physician) from inappropriately and/or inadvertently activating implant 40 (e.g., at an inappropriate time). In the first state, the wireless signals cannot reach (or cannot sufficiently reach) antenna 46. Therefore, the testing of the position of implant 40 cannot be performed in the first state. In the second state, the wireless signals can reach antenna 46, and therefore it is possible, in the second state, to test the position of implant 40. (Naturally, the wireless signals can reach antenna 46 also when tool 100 is in the third state, because in the third state implant 40 is entirely disposed outside of the distal end of needle 102.)


The use of openings 108 is particularly useful for applications in which the material from which needle 102 is formed is opaque to the wireless signals (e.g., a metal). For some applications, the material from which needle 102 is primarily formed may be transparent to the wireless signals (e.g., a polymer). For some such applications, needle 102 may have a metallic portion (e.g., a metallic shell radially inside, outside, or within the polymer, or as a distinct metallic longitudinal section between more proximal and distal polymer longitudinal sections), at the part of the needle at which antenna 46 is disposed in the first state of tool 100. The metallic portion inhibits the wireless signal from reaching (or sufficiently reaching) antenna 46, as described hereinabove, mutatis mutandis. Therefore, in a similar way to that described hereinabove, such a needle would also prevent inappropriate/inadvertent activation of implant 40 while tool 100 is in the first state, but would allow activation of the implant while the tool is in the second state. In a similar way, for some applications needle 102 may be primarily formed from a metal, but openings 108 are replaced by a polymer portion of the needle.


The embodiments described above have the following in common:

    • The hollow needle has (i) a non-blocking longitudinal portion that allows the wireless signal to reach the antenna while the antenna is disposed in the non-blocking portion, and (ii) a blocking longitudinal portion that is significantly more opaque to the wireless signal than is the non-blocking portion, such that it blocks the wireless signal from activating the implant while the antenna is disposed in the blocking portion.
    • In the first state of the tool, the antenna is disposed in the blocking portion of the needle.
    • In the second state of the tool, the antenna is disposed in the non-blocking portion of the needle.
    • In the third state of the tool, the implant is entirely disposed outside of the distal end of the needle.
    • Typically, the non-blocking portion is closer than the blocking portion to the distal end of the needle.


For applications in which (i) in the first state all of electrodes 48 are disposed within needle 102, and (ii) in the second state electrode 48d is exposed from the distal end of the needle, the differing position of the electrodes between the first and second states may further prevent inappropriate and/or inadvertent driving of the current by implant 40. That is, in the first state, implant 40 cannot receive the wireless signals, and electrodes 48 are not exposed for application of current, whereas in the second state, implant 40 can receive the wireless signals, and t least one of electrodes 48 is exposed for application of current.


It is to be noted that, in the context of the first, second and third states of tool 100, the term “state” (including in the specification and the claims) means a discrete pre-configured condition of the tool, such as a condition in which the tool is configured to remain. Thus, tool 100 being configured to define the states means that tool 100 has particular features or elements that define the states and/or retain the tool in the states. For example, tool 100 (e.g., control portion 104) may comprise control elements 110 that enable switching between the states.



FIGS. 2A-H show steps in a technique for using tool 100 to implant implant 40 in a subject, in accordance with some applications of the invention. The example used is implantation of implant 40 close to a tibial nerve 6 of the subject, and in a distal to proximal direction, but the technique may be used at other anatomical sites and/or in other anatomical directions, mutatis mutandis. Each of FIGS. 2A-H shows a longitudinal cross-section and a transverse section of the lower leg 4 of a subject. The longitudinal cross-section illustrates the advancement of needle 102 through the tissue, and the state of tool 100. The transverse cross-section provides more anatomical detail, and schematically shows the depth to which needle 102 has penetrated. In the transverse cross-section, the element labeled 102 schematically represents needle 102. However, although in the transverse cross-section needle 102 should extend into and/or out of the page, a more simple representation is used for the sake of clarity.


Needle 102 (e.g., a tip 120 thereof) is percutaneously advanced into the leg (FIG. 2A). For some applications, and as shown, needle 102 is advanced through the skin while tool 100 is in the first state, with tip 120 thereby defining the leading edge of system 20, e.g., such that needle 102 penetrates the skin. (Alternatively, an incision is made in the skin, and tool 100 is introduced via the incision, e.g., while in the second state). Subsequently, tool 100 is switched to the second state (FIG. 2B). Subsequently, and while tool 100 is in the second state, it is advanced through non-fascia tissue (e.g., fat tissue, and/or connective tissue) 8 of the leg, typically until reaching a fascia 10 (FIG. 2C). That is, system 20 is advanced through the non-fascia tissue with implant 40 distal to needle 102, and defining the leading edge of system 20. Upon reaching a fascia 10, tool 100 is switched to the first state (FIG. 2D), and advanced through the fascia while in the first state (FIG. 2E). Once through the fascia, the tool is switched to the second state (FIG. 2F), and advanced through more tissue 8 (FIG. 2G). As described hereinabove, in the second state it is possible to determine if the current location of implant 40 within the tissue is an effective location for implanting the implant. Once a suitable location of implant 40 is achieved (FIG. 2G), tool 100 is switched to the third state (FIG. 2H). Implant 40 is deployed (i.e., released from tool 100) at the suitable location, e.g., automatically upon tool 100 being switched to the third state, or as a result of a distinct subsequent deployment step.


As described hereinabove, determining that implant 40 is in a suitable location for implantation is achieved by activating the implant and, for example, detecting if the desired effect of the implant on the subject has occurred. It is hypothesized by the inventors that, for some applications, such a technique may be limited when the implant is activated to apply current at a single power level. For example, when a single power level is used, if an effect on the subject is detected when the implant is at a first site, and an effect on the subject is also detected when the implant is at a second site, the technique will not have provided information on which of the two sites is more suitable (e.g., closer to nerve 6). It is hypothesized by the inventors that such a technique may be improved by varying the power level at which implant 40 applies current to the tissue in which it is disposed. For example, if (1) after the effect is detected when the implant is at the first site, the implant is activated again, but using iteratively lower power levels until the effect is reduced (e.g., to below a threshold level, such as until the effect is not detected), and (2) when the lower power level is used at the second site, the effect is detected (and/or is above the threshold level), this indicates that the second site is more suitable (e.g., closer to nerve 6) than is the first site.


There is therefore provided, a method for percutaneously delivering an implant to a target site of a body of a subject, the method comprising:


(1) inserting the implant into the subject's tissue;


(2) activating the implant to apply a current to the subject's tissue at a first site within the tissue at a first power level;


(3) measuring a response of the subject to the application of the current to the first site at the first power level;


(4) in response to detecting that the subject responded in a given manner to the application of the current to the first site at the first power level, iteratively applying current to the first site at lower power levels, until detecting that, at a second power level, the subject no longer responds, in the given manner, to the application of current to the first site; and


(5) subsequently:

    • (a) moving the implant to one or more further sites within the subject's tissue and applying current to the tissue, at the one or more further sites, at the second power level;
    • (b) measuring a response of the subject to the application of current to the subject's tissue at the one or more further sites; and
    • (c) in response to detecting that the subject responds, in the given manner, to application of the current at the second power level at a given one of the one or more further sites, implanting the implant closer to the given site than to the first site.


For applications in which movement of the implant between the sites being tested does not require further penetration of a fascia, this movement of the implant between the sites is typically performed while the delivery tool remains in the second state.


Tip 120 is a beveled tip for penetrating tissue. It is hypothesized by the inventors that beveled tips are important for penetrating fascia 10 (and typically also skin 12), but that some other tissues (e.g., fat tissue and/or connective tissue) can be penetrated by implant 40 itself. Thus, in the technique shown in FIGS. 2A-H, implant 40 is advanced through tissue 8 while tool 100 is in the second state, thereby (as described hereinabove) facilitating identification of an effective location for implanting implant 40. It is further hypothesized by the inventors that as implant 40 becomes close to a target nerve such as tibial nerve 6, advancing the implant while tool 100 is in the second state reduces a likelihood of injuring the nerve or a nearby blood vessel with tip 120.


It is to be noted that the transition of tool 100 between its states is performed by retracting and advancing needle 102 with respect to control portion 104 (e.g., changing the effective length of the needle), rather than by advancing and retracting implant 40. This allows implant 40, once a suitable location has been identified, to be deployed from tool 100 without moving the implant with respect to the surrounding tissue (FIGS. 2G-H).



FIGS. 3A-D show detailed views of tip 120 of needle 102 of tool 100, in accordance with some applications of the invention. Tip 120 has a triple-grind bevel that defines a primary grind 122 (alternatively termed a primary bevel) and two side-grinds 124 (alternatively termed secondary bevels, or lancets). Unlike other triple-grind needles, side-grinds 124 do not extend to meet each other to define a point (i.e., a distal point) at a distal-most part of needle 102 (i.e., at the very tip of the needle). That is, primary grind 122 contributes to the pointedness of the distalmost part 126 of tip 120, but side-grinds 124 do not. Thus, part 126 appears pointed when tip 120 is viewed from the side (e.g., when viewed such that primary grind 122 forms part of the outline of the tip) (e.g., FIG. 3A view D), but appears blunt or rounded when the tip is viewed from above or below (e.g., when viewed such that side-grinds 124 are both visible) (e.g., FIG. 3A views C and F, and FIG. 38). Therefore, side-grinds 124 converge toward distalmost part 126, but even where they are closest to each other (i.e., at or near to part 126), they are spaced apart by a distance d5.


For some applications, primary grind 122 defines an angle of 15-25 (e.g., 18-22, such as 20) degrees with respect to the lateral wall and/or central longitudinal axis ax1 of needle 102. For some applications, side-grinds 124 converge distally at an angle alpha_1 of 65-85 (e.g., 74-78, such as 76) degrees to each other (see FIG. 38). For some applications, distance d5 is 0.1-0.4 mm (e.g., 0.16-0.28 mm, such as 0.22 mm).



FIG. 3C shows a transverse cross-section of tip 120 at section III (shown in FIG. 38), according to some applications of the invention. For such applications, side-grinds 124 face away from primary grind 122. That is, side-grinds 124 are “underneath” the needle, and do not eliminate the sloped surface of primary grind 122. Hence the surface of primary grind 122 is visible in FIG. 3C, In transverse cross-section, the planes of side-grinds 124 are disposed at an angle alpha_2 that is typically 100-150 (e.g., 110-140, e.g., 120-140, such as 130) degrees with respect to each other. For some applications, this is similar to a “back bevel point” needle tip, but without the side-grinds extending to meet each other to define a point at the distal-most part of the needle. Therefore, angle alpha_2 may be described as a back bevel angle.



FIG. 3D shows a transverse cross-section of tip 120, according to some alternative applications of the invention. For such applications, side-grinds 124′ face toward primary grind 122. That is, side-grinds 124′ are on the same side of the needle as primary grind 122, and at the longitudinal portion of the needle at which they are disposed, they eliminate the sloped surface of primary grind 122, leaving a ridge 125. In transverse cross-section, the planes of side-grinds 124′ are disposed at an angle alpha_3 with respect to each other. For some applications, this is similar to a “lancet point” needle tip, but without the side-grinds extending to meet each other to define a point at the distal-most part of the needle. Therefore, angle alpha_3 may be described as a lancet angle.


There is therefore provided, in accordance with some applications of the invention, apparatus for facilitating percutaneous delivery of an implant to a target site of a body of a subject, the apparatus comprising a needle that (1) comprises (a) a distal end; and (b) a proximal end, and (2) defines: (a) a lumen configured to facilitate passage of the implant therethrough, and (b) a triple-grind bevel at the distal end of the needle, the triple-grind bevel defining: (i) a primary grind, and (ii) two side-grinds that do not extend to meet each other to define a point at a distal-most part of the needle.


It is hypothesized by the inventors that tip 120 advantageously has both (i) the tissue-penetrating benefits of existing triple-grind needles, and (ii) a distalmost part that is relatively rounded and less likely to injure a target nerve or an adjacent blood vessel, compared to such existing triple-grind needles.



FIGS. 4A-C show respective views of implant 40. FIG. 4A shows implant 40 in its entirety. As described hereinabove, circuitry 44 and antenna 46 are disposed within implant body 42, and the at least one electrode 48 is disposed on the outside of the implant body. Also as described hereinabove, at least one of electrodes 48 (e.g., distal electrode 48d) is disposed at distal portion 50d. Typically, another electrode (e.g., proximal electrode 48p) is disposed at proximal portion 50p. Antenna 46 is typically disposed proximally from electrode 48d (e.g., within proximal portion 50p).


Implant 40 comprises a cuff 54, which circumscribes a recessed longitudinal portion 56 of implant body 42. FIG. 48 illustrates implant 40 with cuff 54 removed, thereby showing recessed longitudinal portion 56. In the example shown, recessed longitudinal portion 56 is defined by at least part of proximal portion 50p. However, recessed longitudinal portion 56 may alternatively or additionally be defined by at least part of distal portion 50d.


Recessed longitudinal portion 56 is radially recessed with respect to at least one other longitudinal portion of the implant body, such that an outer diameter of the recessed longitudinal portion is less than the outer diameter of the other longitudinal portion. In the example shown, the other longitudinal portion may be a longitudinal portion 58 proximal to portion 56 (e.g., another part of proximal portion 50p), or a longitudinal portion 60 distal to portion 56 (e.g., part of distal portion 50d). For example, an outer diameter d3 of recessed longitudinal portion 56 is less than an outer diameter d4 of portion 58, and is also less than an outer diameter of portion 60 (which may be the same as diameter d4), and therefore does not include the distal end or the proximal end of the implant.


Cuff 54 is configured to be coupled to implant body 42 by being coupled to (e.g., wrapped around) recessed longitudinal portion 56 such that, when the cuff is coupled to portion 56, an outer diameter d1 of the cuff does not exceed diameter d4. For some applications, cuff 54 extends less than 360 degrees (e.g., 340-355 degrees) around implant body 42. Typically, cuff 54 has a thickness of 100-500 (e.g., 200-250, such as 225) microns.


Cuff 54 defines a plurality of holes 62. Each hole 62 may have a diameter of 200-550 (e.g., 280-340) microns. Cuff 54 typically comprises a resilient material. For some applications, cuff 54 comprises polyether ether ketone, polyethylene terephthalate, fluorinated ethylene propylene, polyimide, acrylic, nylon, polytetrafluoroethylene, or polyetherimide (e.g., Ultem). This material and/or holes 62 increase the resistance of cuff 54, and therefore implant 40, to movement once implanted in tissue (e.g., the cuff grips the tissue). That is, cuff 54 serves as an anchor. Because diameter d1 does not exceed diameter d4, cuff 54 does not grip the inside of needle 102 (i.e., does not increase friction of the implant against the inside of the needle), and thereby does not interfere with movement of implant 40 within the needle during delivery and deployment of the implant. Holes 62 are further configured to facilitate anchoring of implant 40 with respect to the tissue, by facilitating tissue growth into the holes.



FIG. 4C shows implant 40 with electrodes 48 and most of implant body 42 removed, thereby showing antenna 46 and circuitry 44. For some applications, and as shown, antenna 46 is disposed in recessed longitudinal portion 56.


It is to be noted that for some applications tool 100 may be used to deliver implants other than implant 40. For example, tool 100 may be used to deliver a different electrostimulator implant, or an implant that is not an electrostimulator implant. It is to be further noted that, for some applications, needle 102 (e.g., tip 120 thereof) may be used in delivery tools other than tool 100. It is to be further noted that needle 102 may be useful for applications other than percutaneous implantation of an implant.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. Apparatus for facilitating percutaneous delivery of an implant to a target site of a body of a subject, the apparatus comprising a delivery tool, the delivery tool comprising a needle, the needle comprising: a distal end; anda proximal end,the needle defining: a lumen configured to facilitate passage of the implant therethrough,lateral openings in a wall of the needle, the openings being proximal from the distal end of the needle, anda triple-grind bevel at the distal end of the needle, the triple-grind bevel defining: a primary grind, andtwo side-grinds that do not extend to meet each other to define a point at a distal-most part of the needle.
  • 2. The apparatus according to claim 1, wherein the two side-grinds converge distally at an angle of 65-85 degrees to each other.
  • 3. A system comprising the apparatus according to 1, further comprising the implant.
  • 4. The apparatus according to claim 1, wherein the side-grinds converge distally, but at the distal-most part of the needle, the side-grinds are spaced apart by 0.1-0.4 mm.
  • 5. A system comprising the apparatus according to claim 1, the system further comprising the implant, the implant comprising an antenna, and the delivery tool being configured to define: a first state, in which the implant is housed within the lumen of the needle such that the antenna is disposed proximally from the lateral openings,a second state, in which a distal portion of the implant is exposed from a distal end of the needle, and the antenna is aligned with the lateral openings, anda third state, in which the implant is entirely disposed outside of the distal end of the needle.
  • 6. The system according to claim 5, wherein in the first state, the entire implant is disposed within the needle.
  • 7. The system according to claim 5, wherein in the first state, the entire implant is disposed proximally from the lateral openings.
  • 8. The system according to claim 5, wherein in the first state, the distal portion of the implant is aligned with the lateral openings.
  • 9. The system according to claim 5, wherein: the implant is an electrostimulator implant, and comprises: an implant body, the implant being injectable into tissue of the subject along a longitudinal axis of the implant body, the antenna disposed within the implant body;a proximal electrode disposed on the implant body, anda distal electrode disposed on the implant body distally from the proximal electrode, andin the second state of the delivery tool, the distal electrode is exposed from the distal end of the needle.
  • 10. The system according to claim 9, wherein in the first state of the delivery tool, the proximal electrode and the distal electrode are disposed within the needle.
  • 11. The system according to claim 9, wherein: the implant body has a recessed longitudinal portion that is radially recessed with respect to another longitudinal portion of the implant body, such that an outer diameter of the recessed longitudinal portion is less than the outer diameter of the other longitudinal portion,the antenna is disposed in the recessed longitudinal portion, andthe distal electrode is disposed on the other longitudinal portion.
  • 12. The system according to claim 11, wherein the recessed longitudinal portion is configured to facilitate reception of a wireless signal, by the antenna, while the delivery tool is in the second state and while the delivery tool is in the third state.
  • 13. The system according to claim 5, wherein the antenna is configured to receive energy wirelessly.
  • 14. Apparatus for facilitating percutaneous delivery of an implant to a target site of a body of a subject, the apparatus comprising a delivery tool, the delivery tool comprising a needle, the needle comprising: a distal end; anda proximal end,the needle defining: a lumen configured to facilitate passage of the implant therethrough, anda triple-grind bevel at the distal end of the needle, the triple-grind bevel defining: a primary grind, andtwo side-grinds that converge distally, but at the distal-most part of the needle, are spaced apart by 0.1-0.4 mm.
  • 15. A system comprising the apparatus according to claim 14, the system further comprising the implant, the implant comprising an antenna, wherein: the needle defines lateral openings in a wall of the needle, the openings being proximal from the distal end of the needle; andthe delivery tool is configured to define: a first state, in which the implant is housed within the lumen of the needle such that the antenna is disposed proximally from the lateral openings,a second state, in which a distal portion of the implant is exposed from a distal end of the needle, and the antenna is aligned with the lateral openings, anda third state, in which the implant is entirely disposed outside of the distal end of the needle.
  • 16. The system according to claim 15, wherein in the first state, the entire implant is disposed within the needle.
  • 17. The system according to claim 15, wherein in the first state, the entire implant is disposed proximally from the lateral openings.
  • 18. The system according to claim 15, wherein in the first state, the distal portion of the implant is aligned with the lateral openings.
  • 19. Apparatus for facilitating percutaneous delivery of an implant to a target site of a body of a subject, the apparatus comprising a delivery tool, the delivery tool comprising a needle, the needle comprising: a distal end; anda proximal end,the needle defining: a lumen configured to facilitate passage of the implant therethrough, anda triple-grind bevel at the distal end of the needle, the triple-grind bevel defining: a primary grind, andtwo side-grinds that: converge distally at an angle of 65-85 degrees to each other, anddo not extend to meet each other to define a point at a distal-most part of the needle.
  • 20. A system comprising the apparatus according to claim 19, the system further comprising the implant, the implant comprising an antenna, wherein: the needle defines lateral openings in a wall of the needle, the openings being proximal from the distal end of the needle; and
CROSS-REFERENCES TO RELATED APPLICATIONS

This patent application is a Continuation of U.S. Ser. No. 16/183,783 to Oron et al., filed Nov. 8, 2018, and entitled “Implant and delivery tool therefor,” which issued as U.S. Pat. No. 10,744,331, and which is a Continuation of U.S. Ser. No. 15/360,501 to Oron et al., filed Nov. 23, 2016, and entitled “Implant and delivery tool therefor,” which issued as U.S. Pat. No. 10,124,178.

US Referenced Citations (732)
Number Name Date Kind
3411507 Wingrove Nov 1968 A
3693625 Auphan Sep 1972 A
3727616 Lenzkes Apr 1973 A
4019518 Maurer et al. Apr 1977 A
4338945 Kosugi et al. Jul 1982 A
4392496 Stanton Jul 1983 A
4535785 Van Den Honert Aug 1985 A
4559948 Liss et al. Dec 1985 A
4573481 Bullara Mar 1986 A
4585005 Lue et al. Apr 1986 A
4602624 Naples Jul 1986 A
4608985 Crish Sep 1986 A
4628942 Sweeney Dec 1986 A
4632116 Rosen Dec 1986 A
4649936 Ungar Mar 1987 A
4663102 Brenman et al. May 1987 A
4739764 Lau Apr 1988 A
4808157 Coombs Feb 1989 A
4867164 Zabara Sep 1989 A
4926865 Oman May 1990 A
4962751 Krauter Oct 1990 A
5025807 Zabara Jun 1991 A
5036854 Schollmeyer et al. Aug 1991 A
5069680 Grandjean Dec 1991 A
5178161 Kovacs Jan 1993 A
5188104 Wernicke Feb 1993 A
5199428 Obel et al. Apr 1993 A
5199430 Fang Apr 1993 A
5203326 Collins Apr 1993 A
5205285 Baker, Jr. Apr 1993 A
5215086 Terry, Jr. Jun 1993 A
5263480 Wernicke Nov 1993 A
5282468 Klepinski Feb 1994 A
5284479 De Jong Feb 1994 A
5292344 Douglas Mar 1994 A
5299569 Wernicke Apr 1994 A
5314495 Kovacs May 1994 A
5330507 Schwartz Jul 1994 A
5335657 Terry, Jr. Aug 1994 A
5344439 Otten Sep 1994 A
5411535 Fujii et al. May 1995 A
5423872 Cigaina Jun 1995 A
5439938 Synder et al. Aug 1995 A
5454840 Krakovsky et al. Oct 1995 A
5487760 Villafana Jan 1996 A
5505201 Grill, Jr. Apr 1996 A
5540730 Terry, Jr. Jul 1996 A
5540733 Testerman et al. Jul 1996 A
5540734 Zabara Jul 1996 A
5549655 Erickson Aug 1996 A
5571150 Wernicke Nov 1996 A
5591216 Testerman et al. Jan 1997 A
5634462 Tyler et al. Jun 1997 A
5690681 Geddes et al. Nov 1997 A
5690691 Chen Nov 1997 A
5700282 Zabara Dec 1997 A
5707400 Terry, Jr. Jan 1998 A
5711316 Elsberry et al. Jan 1998 A
5716385 Mittal Feb 1998 A
5755750 Petruska May 1998 A
5776170 Macdonald et al. Jul 1998 A
5776171 Peckham Jul 1998 A
5814089 Stokes Sep 1998 A
5824027 Hoffer et al. Oct 1998 A
5832932 Elsberry et al. Nov 1998 A
5833709 Rise et al. Nov 1998 A
5836994 Bourgeois Nov 1998 A
5861019 Sun et al. Jan 1999 A
5916239 Geddes et al. Jun 1999 A
5938584 Ardito et al. Aug 1999 A
5944680 Christopherson Aug 1999 A
5954758 Peckham Sep 1999 A
5991664 Seligman Nov 1999 A
6002964 Feler et al. Dec 1999 A
6026326 Bardy Feb 2000 A
6026328 Peckham Feb 2000 A
6032076 Melvin et al. Feb 2000 A
6058331 King et al. May 2000 A
6066163 John May 2000 A
6071274 Thompson et al. Jun 2000 A
6091992 Bourgeois Jun 2000 A
6083249 Familoni Jul 2000 A
6086525 Davey et al. Jul 2000 A
6091977 Tarjan et al. Jul 2000 A
6094598 Elsberry et al. Jul 2000 A
6097984 Douglas Aug 2000 A
6104955 Bourgeois Aug 2000 A
6104960 Duysens et al. Aug 2000 A
6119516 Hock Sep 2000 A
6146335 Gozani Nov 2000 A
6148232 Avrahami Nov 2000 A
6161048 Sluijter et al. Dec 2000 A
6169924 Meloy et al. Jan 2001 B1
6205359 Boveja Mar 2001 B1
6212435 Lattner et al. Apr 2001 B1
6214032 Loeb et al. Apr 2001 B1
6230061 Hartung May 2001 B1
6240316 Richmond May 2001 B1
6246912 Sluijter et al. Jun 2001 B1
6266564 Schwartz Jul 2001 B1
6272383 Grey Aug 2001 B1
6292703 Meier et al. Sep 2001 B1
6319241 King Nov 2001 B1
6332089 Acker Dec 2001 B1
6341236 Osorio et al. Jan 2002 B1
6345202 Richmond et al. Feb 2002 B2
6356784 Lozano et al. Mar 2002 B1
6356788 Boveja Mar 2002 B2
6366813 Dilorenzo Apr 2002 B1
6405079 Ansarinia Jun 2002 B1
6442432 Lee Aug 2002 B2
6445953 Bulkes et al. Sep 2002 B1
6449507 Hill et al. Sep 2002 B1
6456878 Yerich et al. Sep 2002 B1
6463328 John Oct 2002 B1
6473644 Terry, Jr. et al. Oct 2002 B1
6493585 Plicchi et al. Dec 2002 B2
6496729 Thompson Dec 2002 B2
6496730 Kleckner et al. Dec 2002 B1
6582441 He et al. Jun 2003 B1
6591139 Loftin et al. Jul 2003 B2
6600954 Cohen Jul 2003 B2
6600956 Maschino et al. Jul 2003 B2
6606521 Paspa et al. Aug 2003 B2
6610713 Tracey Aug 2003 B2
6618627 Lattner et al. Sep 2003 B2
6641542 Cho et al. Nov 2003 B2
6682480 Habib et al. Jan 2004 B1
6712772 Cohen et al. Mar 2004 B2
6721603 Zabara et al. Apr 2004 B2
6735474 Loeb et al. May 2004 B1
6735475 Whitehurst et al. May 2004 B1
6770022 Mechlenburg Aug 2004 B2
6788973 Davis et al. Sep 2004 B2
6788975 Whitehurst et al. Sep 2004 B1
6804561 Stover Oct 2004 B2
6829508 Schulman Dec 2004 B2
6839594 Cohen Jan 2005 B2
6892098 Ayal May 2005 B2
6907295 Gross et al. Jun 2005 B2
6909917 Woods et al. Jun 2005 B2
6950706 Rodriguez et al. Sep 2005 B2
6993384 Bradley et al. Jan 2006 B2
7015769 Schulman et al. Mar 2006 B2
7025730 Cho et al. Apr 2006 B2
7027860 Bruninga et al. Apr 2006 B2
7047076 Li et al. May 2006 B1
7054689 Whitehurst et al. May 2006 B1
7054692 Whitehurst et al. May 2006 B1
7070583 Higuchi Jul 2006 B1
7110820 Tcheng et al. Sep 2006 B2
7149575 Ostroff et al. Dec 2006 B2
7151914 Brewer Dec 2006 B2
7174218 Kuzma Feb 2007 B1
7177690 Woods et al. Feb 2007 B2
7177698 Klosterman et al. Feb 2007 B2
7190998 Shalev et al. Mar 2007 B2
7203549 Schommer et al. Apr 2007 B2
7209792 Parramon et al. Apr 2007 B1
7212867 Venrooij et al. May 2007 B2
7216000 Sieracki et al. May 2007 B2
7225032 Schmeling et al. May 2007 B2
7228178 Carroll Jun 2007 B2
7239921 Canfield et al. Jul 2007 B2
7242982 Singhal et al. Jul 2007 B2
7254449 Karunasiri Aug 2007 B2
7263402 Thacker et al. Aug 2007 B2
7277748 Wingeier et al. Oct 2007 B2
7277749 Gordon et al. Oct 2007 B2
7286880 Olson et al. Oct 2007 B2
7286881 Schommer et al. Oct 2007 B2
7289853 Campbell et al. Oct 2007 B1
7292890 Whitehurst et al. Nov 2007 B2
7308316 Schommer Dec 2007 B2
7324852 Barolat et al. Jan 2008 B2
7324853 Ayal Jan 2008 B2
7330756 Marnfeldt Feb 2008 B2
7337007 Nathan et al. Feb 2008 B2
7342508 Morgan et al. Mar 2008 B2
7363087 Nghiem et al. Apr 2008 B2
7376466 He et al. May 2008 B2
7389145 Kilgore et al. Jun 2008 B2
7483748 Torgerson et al. Jan 2009 B2
7483752 Von arx et al. Jan 2009 B2
7489561 Armstrong et al. Feb 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7515012 Schulman et al. Apr 2009 B2
7515967 Phillips et al. Apr 2009 B2
7532932 Denker et al. May 2009 B2
7536226 Williams May 2009 B2
7539538 Parramon et al. May 2009 B2
7561921 Phillips et al. Jul 2009 B2
7565204 Matei Jul 2009 B2
7628750 Cohen Dec 2009 B2
7630771 Cauller Dec 2009 B2
7634313 Kroll et al. Dec 2009 B1
7643147 Pless Jan 2010 B2
7647117 Bauhahn Jan 2010 B2
7650192 Wahlstrand Jan 2010 B2
7655014 Ko et al. Feb 2010 B2
7657311 Bardy et al. Feb 2010 B2
7657317 Thacker et al. Feb 2010 B2
7657322 Bardy et al. Feb 2010 B2
7660632 Kirby et al. Feb 2010 B2
7680538 Durand et al. Mar 2010 B2
7680540 Jensen et al. Mar 2010 B2
7711434 Denker et al. May 2010 B2
7736379 Ewers et al. Jun 2010 B2
7747325 Dilorenzo Jun 2010 B2
7780625 Bardy Aug 2010 B2
7797050 Libbus et al. Sep 2010 B2
7801602 McClure et al. Sep 2010 B2
7803142 Longson et al. Sep 2010 B2
7809437 Palmer et al. Oct 2010 B2
7817280 Pless Oct 2010 B2
7822480 Park et al. Oct 2010 B2
7848818 Barolat et al. Dec 2010 B2
7869867 Armstrong et al. Jan 2011 B2
7894905 Pless et al. Feb 2011 B2
7899547 Emadi et al. Mar 2011 B1
7899556 Nathan et al. Mar 2011 B2
7904171 Parramon et al. Mar 2011 B2
7912551 Wosmek Mar 2011 B2
7925350 Palmer Apr 2011 B1
7917226 Nghiem May 2011 B2
7937148 Jacobson May 2011 B2
7941218 Sambelashvili et al. May 2011 B2
7962211 Torgerson et al. Jun 2011 B2
7962220 Kolafa et al. Jun 2011 B2
7974706 Moffitt et al. Jul 2011 B2
7979126 Payne et al. Jul 2011 B2
7991467 Markowitz et al. Aug 2011 B2
7996079 Armstrong Aug 2011 B2
7996089 Haugland et al. Aug 2011 B2
7996092 Mrva et al. Aug 2011 B2
8005547 Forsberg et al. Aug 2011 B2
8019443 Scheicher et al. Sep 2011 B2
8050771 Yamamoto et al. Nov 2011 B2
8055336 Schulman et al. Nov 2011 B1
8055350 Roberts Nov 2011 B2
8075556 Betts Dec 2011 B2
8086313 Singhal et al. Dec 2011 B2
8090438 Bardy et al. Jan 2012 B2
8115448 John Feb 2012 B2
8127424 Haller et al. Mar 2012 B2
8131377 Shhi et al. Mar 2012 B2
8140168 Olson et al. Mar 2012 B2
8170675 Alataris et al. May 2012 B2
8170681 Jimenez et al. May 2012 B2
8175719 Shi et al. May 2012 B2
8177792 Lubock et al. May 2012 B2
8185207 Molnar et al. May 2012 B2
8209021 Alataris et al. Jun 2012 B2
8224453 De Ridder Jul 2012 B2
8229567 Phillips et al. Jul 2012 B2
8244367 Wahlstrand et al. Aug 2012 B2
8255057 Fang et al. Aug 2012 B2
8260432 DiGiore et al. Sep 2012 B2
8265770 Toy et al. Sep 2012 B2
8306627 Armstrong Nov 2012 B2
8311638 Aghassian Nov 2012 B2
8321028 Thenuwara et al. Nov 2012 B1
8335569 Aghassian Dec 2012 B2
8355792 Alataris et al. Jan 2013 B2
8359102 Alataris et al. Jan 2013 B2
8359103 Alataris et al. Jan 2013 B2
8364267 Schleicher et al. Jan 2013 B2
8369963 Parramon et al. Feb 2013 B2
8374700 Haubrich et al. Feb 2013 B2
8386047 Koester Feb 2013 B2
8386048 McClure et al. Feb 2013 B2
8396559 Alataris et al. Mar 2013 B2
8428731 Armstrong Apr 2013 B2
8428744 Stancer et al. Apr 2013 B2
8428746 Digiore et al. Apr 2013 B2
8428748 Alataris et al. Apr 2013 B2
8437846 Swoyer et al. May 2013 B2
8437853 Inman et al. May 2013 B2
8457744 Janzig et al. Jun 2013 B2
8457759 Parker et al. Jun 2013 B2
8463404 Levi et al. Jun 2013 B2
8473066 Aghassian et al. Jun 2013 B2
8478420 Armstrong et al. Jul 2013 B2
8483838 Nghiem et al. Jul 2013 B2
8483845 Sage Jul 2013 B2
8494640 Peterson et al. Jul 2013 B2
8494650 Glukhovsky et al. Jul 2013 B2
8497804 Haubrich et al. Jul 2013 B2
8498716 Chen et al. Jul 2013 B2
8509905 Alataris et al. Aug 2013 B2
8509906 Walker et al. Aug 2013 B2
8515558 Zweber et al. Aug 2013 B1
8538548 Shi et al. Sep 2013 B2
8543200 Lane et al. Sep 2013 B2
8554326 Alataris et al. Oct 2013 B2
8555894 Schulman et al. Oct 2013 B2
8571651 Ben-ezra et al. Oct 2013 B2
8577474 Rahman et al. Nov 2013 B2
8588933 Floyd et al. Nov 2013 B2
8612014 Rahman et al. Dec 2013 B2
8612019 Moffitt Dec 2013 B2
8620435 Rooney et al. Dec 2013 B2
8620449 Zhao et al. Dec 2013 B2
8626310 Barror et al. Jan 2014 B2
8634927 Olson et al. Jan 2014 B2
8644947 Zhu et al. Feb 2014 B2
8644948 Grevious et al. Feb 2014 B2
8649874 Alataris et al. Feb 2014 B2
8660655 Peterson et al. Feb 2014 B2
8666491 Chen et al. Mar 2014 B2
8666504 Dronov et al. Mar 2014 B2
8676337 Kallmyer Mar 2014 B2
8676341 Kane et al. Mar 2014 B2
8688232 Finley et al. Apr 2014 B2
8694108 Alataris et al. Apr 2014 B2
8694109 Alataris et al. Apr 2014 B2
8712533 Alataris et al. Apr 2014 B2
8712534 Wei Apr 2014 B2
8718780 Lee May 2014 B2
8718781 Alataris et al. May 2014 B2
8718782 Alataris et al. May 2014 B2
8738145 Goetz et al. May 2014 B2
8750985 Parramon et al. Jun 2014 B2
8751009 Wacnik Jun 2014 B2
8755893 Gross et al. Jun 2014 B2
8761895 Stevenson et al. Jun 2014 B2
8768472 Fang et al. Jul 2014 B2
8774912 Gerber Jul 2014 B2
8774926 Alataris et al. Jul 2014 B2
8788045 Gross et al. Jul 2014 B2
8792988 Alataris et al. Jul 2014 B2
8798773 Mashiach Aug 2014 B2
8805519 Parker et al. Aug 2014 B2
8812135 Mashiach Aug 2014 B2
8843203 Lee et al. Sep 2014 B2
8849410 Walker et al. Sep 2014 B2
8849412 Perryman et al. Sep 2014 B2
8862239 Alataris et al. Oct 2014 B2
8868192 Alataris et al. Oct 2014 B2
8874217 Alataris et al. Oct 2014 B2
8874219 Trier et al. Oct 2014 B2
8874221 Alataris et al. Oct 2014 B2
8874222 Alataris et al. Oct 2014 B2
8880177 Alataris et al. Nov 2014 B2
8884779 Herman et al. Nov 2014 B2
8886326 Alataris et al. Nov 2014 B2
8886327 Alataris et al. Nov 2014 B2
8886328 Alataris et al. Nov 2014 B2
8892209 Alataris et al. Nov 2014 B2
8892214 Bonde et al. Nov 2014 B2
8903497 Norgaard et al. Dec 2014 B2
8903499 Pless et al. Dec 2014 B2
8918179 Peterson et al. Dec 2014 B2
8918180 Peterson Dec 2014 B2
8923988 Bradley Dec 2014 B2
8942808 Peterson et al. Jan 2015 B2
8954165 Sharma et al. Feb 2015 B2
8958884 Kothandaraman et al. Feb 2015 B2
8958891 Kane et al. Feb 2015 B2
8983615 Tahmasian et al. Mar 2015 B2
8983618 Yamamoto et al. Mar 2015 B2
8989864 Funderburk et al. Mar 2015 B2
8989868 Mashiach et al. Mar 2015 B2
8994325 Carbunaru et al. Mar 2015 B2
8996115 Trier et al. Mar 2015 B2
9002445 Chen Apr 2015 B2
9002460 Parker Apr 2015 B2
9002461 Walker et al. Apr 2015 B2
9002466 Trier et al. Apr 2015 B2
9020599 Rooney et al. Apr 2015 B2
9020602 Aghassian Apr 2015 B2
9026227 Daglow May 2015 B2
9030159 Chen et al. May 2015 B2
9031666 Fell May 2015 B2
9037261 Bradley May 2015 B2
9042997 Rahman et al. May 2015 B2
9044616 Chen et al. Jun 2015 B2
9056206 Torgerson et al. Jun 2015 B2
9061140 Shi et al. Jun 2015 B2
9061151 Mashiach et al. Jun 2015 B2
9061159 Rahman Jun 2015 B2
9061162 Mashiach et al. Jun 2015 B2
9067072 Tahmasian et al. Jun 2015 B2
9070507 Dronov et al. Jun 2015 B2
9072896 Dar et al. Jul 2015 B2
9079041 Park et al. Jul 2015 B2
9084900 Hershey et al. Jul 2015 B2
9089712 Joshi et al. Jul 2015 B2
9095726 Parramon et al. Aug 2015 B2
9101774 Mashiach et al. Aug 2015 B2
9119969 Vansickle Sep 2015 B2
9142989 Fell et al. Sep 2015 B2
9149635 Denison et al. Oct 2015 B2
9149643 Tahmasian et al. Oct 2015 B2
9154219 Polefko et al. Oct 2015 B2
9155899 Mashiach et al. Oct 2015 B2
9155901 Dearden et al. Oct 2015 B2
9162068 Dronov Oct 2015 B2
9174051 Marnfeldt et al. Nov 2015 B2
9174053 Zhu Nov 2015 B2
9186504 Gross Nov 2015 B2
9192770 Wang et al. Nov 2015 B2
9199083 Caparso et al. Dec 2015 B2
9205258 Simon et al. Dec 2015 B2
9211418 Aghassian Dec 2015 B2
9216297 Kast et al. Dec 2015 B2
9220907 Mashiach et al. Dec 2015 B2
9220909 Carbunaru et al. Dec 2015 B2
9220910 Colborn Dec 2015 B2
9225194 Joshi Dec 2015 B2
9227075 Aghassian et al. Jan 2016 B2
9232903 Pless et al. Jan 2016 B2
9238138 Lee et al. Jan 2016 B2
9240630 Joshi Jan 2016 B2
9242106 Klosterman et al. Jan 2016 B2
9248279 Chen et al. Feb 2016 B2
9248292 Trier et al. Feb 2016 B2
9248302 Mashiach et al. Feb 2016 B2
9254393 Perryman et al. Feb 2016 B2
9259571 Straka et al. Feb 2016 B2
9259582 Joshi et al. Feb 2016 B2
9259584 Bauhahn et al. Feb 2016 B2
9265941 Van Den Biggelaar et al. Feb 2016 B2
9265958 Joshi et al. Feb 2016 B2
9289616 Koester Mar 2016 B2
9295841 Fang et al. Mar 2016 B2
9295850 Kallmyer Mar 2016 B2
9314613 Mashiach Apr 2016 B2
9314628 North et al. Apr 2016 B2
9314642 Ozawa et al. Apr 2016 B2
9320847 Rooney et al. Apr 2016 B2
9320899 Parramon et al. Apr 2016 B2
9320908 Fletcher et al. Apr 2016 B2
9333367 Chen May 2016 B2
9339660 Feldman et al. May 2016 B2
9343923 Joshi May 2016 B2
9352161 Thacker et al. May 2016 B2
9370664 Marnfeldt et al. Jun 2016 B2
9375582 Kaula et al. Jun 2016 B2
9381360 Hershey Jul 2016 B2
9387331 Zhao et al. Jul 2016 B2
9387332 Zhao et al. Jul 2016 B2
9393423 Parramon et al. Jul 2016 B2
9393428 Nyberg, II et al. Jul 2016 B2
9393435 Mashiach Jul 2016 B2
9398901 Tischendorf et al. Jul 2016 B2
9399130 Bonde et al. Jul 2016 B2
9399131 Digiore et al. Jul 2016 B2
9399143 Yamamoto et al. Jul 2016 B2
9403013 Walker et al. Aug 2016 B2
9403020 Wingeier Aug 2016 B2
9403021 Dronov Aug 2016 B2
9407110 Lui et al. Aug 2016 B2
9409029 Perryman et al. Aug 2016 B2
9435830 Joshi Sep 2016 B2
9446251 Perryman et al. Sep 2016 B1
9446254 Ozawa et al. Sep 2016 B2
9449501 Grevious et al. Sep 2016 B2
9452288 Whitehurst et al. Sep 2016 B2
9457186 Gross Oct 2016 B2
9463321 Bradley et al. Oct 2016 B2
9463323 Lee et al. Oct 2016 B2
9463326 Ranu Oct 2016 B2
9468771 Griffith et al. Oct 2016 B2
9468772 Demmer Oct 2016 B2
9469437 Kamath Oct 2016 B2
9474905 Doan et al. Oct 2016 B2
9480841 Hershey et al. Nov 2016 B2
9504832 Libbus et al. Nov 2016 B2
9504838 Rao et al. Nov 2016 B2
9517344 Bradley Dec 2016 B1
9517352 Kast et al. Dec 2016 B2
9522270 Perryman et al. Dec 2016 B2
9533148 Carcieri Jan 2017 B2
9533153 Libbus et al. Jan 2017 B2
9533154 Kothandaraman et al. Jan 2017 B2
9533162 Ter-petrosyan et al. Jan 2017 B2
9555257 Mashiach et al. Jan 2017 B2
9561365 Shi et al. Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9586054 Aghassian Mar 2017 B2
9592385 Kaula et al. Mar 2017 B2
9597516 Lee et al. Mar 2017 B2
9597517 Moffitt Mar 2017 B2
9597521 Plotkin et al. Mar 2017 B2
9610450 Zhao Apr 2017 B2
9616230 Grandhe Apr 2017 B2
9623244 Kothandaraman Apr 2017 B2
9623245 King et al. Apr 2017 B2
9623253 Perryman et al. Apr 2017 B2
9623257 Olson et al. Apr 2017 B2
9630231 Kelsch et al. Apr 2017 B2
9636508 Chen et al. May 2017 B2
9643022 Mashiach et al. May 2017 B2
9649049 Pless et al. May 2017 B2
9649493 Mashiach May 2017 B2
9653941 Dinsmoor et al. May 2017 B2
9656074 Simon et al. May 2017 B2
9656076 Trier et al. May 2017 B2
9656081 Feldman et al. May 2017 B2
9675809 Chow Jun 2017 B2
9687649 Thacker Jun 2017 B2
9700725 Zhu Jul 2017 B2
9700730 Carbunaru et al. Jul 2017 B2
9707404 Rao et al. Jul 2017 B2
9713707 Oron et al. Jul 2017 B2
9713717 Aghassian Jul 2017 B2
9713718 Lamont et al. Jul 2017 B2
9713721 Kothandaraman Jul 2017 B2
9724513 Lane et al. Aug 2017 B2
9731116 Chen Aug 2017 B2
9737703 Carbunaru et al. Aug 2017 B2
9737714 Zottola Aug 2017 B2
9744347 Chen et al. Aug 2017 B2
9744362 Steinke et al. Aug 2017 B2
9744365 Davis et al. Aug 2017 B2
9744368 Dinsmoor Aug 2017 B2
9750930 Chen Sep 2017 B2
9782588 Shi et al. Oct 2017 B2
9782593 Parramon et al. Oct 2017 B2
9782596 Vamos et al. Oct 2017 B2
9789314 Perryman et al. Oct 2017 B2
9789321 Dixit et al. Oct 2017 B2
9789324 Bauhahn et al. Oct 2017 B2
9802038 Lee et al. Oct 2017 B2
9802048 Armstrong Oct 2017 B2
9802052 Marnfeldt Oct 2017 B2
9814458 North Nov 2017 B2
9814880 Hershey et al. Nov 2017 B2
9814884 Parker et al. Nov 2017 B2
9839786 Rondoni et al. Dec 2017 B2
9844677 Aghassian Dec 2017 B2
9849298 Ozawa et al. Dec 2017 B2
9855436 Dearden et al. Jan 2018 B2
9861812 Gross et al. Jan 2018 B2
9861825 Ozawa et al. Jan 2018 B2
9867989 Blum et al. Jan 2018 B2
9867994 Parramon Jan 2018 B2
9878158 Hershey et al. Jan 2018 B2
9913980 Ostroff et al. Mar 2018 B2
9913986 Chow et al. Mar 2018 B2
9913990 Ter-Petrosyan et al. Mar 2018 B2
9925381 Nassif Mar 2018 B2
9929584 Aghassian et al. Mar 2018 B2
9931107 Tischendorf et al. Apr 2018 B2
9935498 Joshi Apr 2018 B2
9943685 Ramesh et al. Apr 2018 B2
9950166 Mashiach et al. Apr 2018 B2
9950173 Doan Apr 2018 B2
9950179 Bonde et al. Apr 2018 B2
9956419 Bokil May 2018 B2
9956421 Bunyan et al. May 2018 B2
9974965 Perryman et al. May 2018 B2
9981130 Lee May 2018 B2
9993645 Walker et al. Jun 2018 B2
10004896 Oron et al. Jun 2018 B2
10010717 Aghassian et al. Jul 2018 B2
10014571 Andersen et al. Jul 2018 B2
10056688 Andersen et al. Aug 2018 B2
10058705 Andersen et al. Aug 2018 B2
10064288 Li et al. Aug 2018 B2
10080902 Dinsmoor et al. Sep 2018 B2
10105540 Oron et al. Oct 2018 B2
10105542 Jiang et al. Oct 2018 B2
10105543 Marnfeldt et al. Oct 2018 B2
10118040 Zhu Nov 2018 B2
10124178 Oron et al. Nov 2018 B2
10143845 Kothandaraman Dec 2018 B2
10149976 Andresen et al. Dec 2018 B1
10173062 Parker Jan 2019 B2
10177609 Olson et al. Jan 2019 B2
10179241 Walker et al. Jan 2019 B2
10182807 Bridgeman et al. Jan 2019 B2
10195425 Ostroff et al. Feb 2019 B2
10213608 Moffitt Feb 2019 B2
10219229 Mulligan, IV Feb 2019 B1
10226637 Aghassian et al. Mar 2019 B2
10238863 Gross et al. Mar 2019 B2
10449374 Oron et al. Oct 2019 B2
10532208 Ostroff et al. Jan 2020 B2
10583284 Peters et al. Mar 2020 B2
10744331 Oron et al. Aug 2020 B2
20020077554 Schwartz et al. Jun 2002 A1
20020099419 Cohen et al. Jul 2002 A1
20020124848 Sullivan et al. Sep 2002 A1
20020183805 Fang et al. Dec 2002 A1
20020183817 Van Venrooij et al. Dec 2002 A1
20030014016 Purdy Jan 2003 A1
20030040774 Terry et al. Feb 2003 A1
20030060858 Kieval et al. Mar 2003 A1
20030100933 Ayal May 2003 A1
20030114905 Kuzma Jun 2003 A1
20030176898 Gross et al. Sep 2003 A1
20030236557 Whitehurst et al. Dec 2003 A1
20030236558 Whitehurst et al. Dec 2003 A1
20040015205 Whitehurst et al. Jan 2004 A1
20040019368 Lattner et al. Jan 2004 A1
20040048795 Ivanova et al. Mar 2004 A1
20040073270 Firlik et al. Apr 2004 A1
20040254624 Johnson Jun 2004 A1
20040153074 Bojarski et al. Aug 2004 A1
20040167584 Carroll et al. Aug 2004 A1
20040249431 Ransbury et al. Dec 2004 A1
20040254612 Ezra et al. Dec 2004 A1
20050113894 Zilberman et al. May 2005 A1
20050131495 Parramon et al. Jun 2005 A1
20050143789 Whitehurst Jun 2005 A1
20050165457 Benser et al. Jul 2005 A1
20050182457 Throne et al. Aug 2005 A1
20050251061 Schuler et al. Nov 2005 A1
20060085039 Hastings et al. Apr 2006 A1
20060085042 Hastings et al. Apr 2006 A1
20060100668 Ben-David et al. May 2006 A1
20060155345 Williams et al. Jul 2006 A1
20060271137 Stanton-Hicks Nov 2006 A1
20070032827 Katims Feb 2007 A1
20070067000 Strother et al. Mar 2007 A1
20070067007 Schulman Mar 2007 A1
20070073353 Rooney et al. Mar 2007 A1
20070073354 Knudson et al. Mar 2007 A1
20070083240 Peterson et al. Apr 2007 A1
20070088397 Jacobson Apr 2007 A1
20070173893 Pitts Jul 2007 A1
20070208392 Kuschner et al. Sep 2007 A1
20070255369 Bonde et al. Nov 2007 A1
20070293908 Cowan et al. Dec 2007 A1
20070293912 Cowan et al. Dec 2007 A1
20080009914 Buysman et al. Jan 2008 A1
20080021336 Dobak Jan 2008 A1
20080027513 Carbunaru Jan 2008 A1
20080039915 Van Den Biggelaar Feb 2008 A1
20080065182 Strother et al. Mar 2008 A1
20080071178 Greenland et al. Mar 2008 A1
20080091255 Caparso et al. Apr 2008 A1
20080103407 Bolea et al. May 2008 A1
20080103572 Gerber May 2008 A1
20080109054 Hastings et al. May 2008 A1
20080119911 Rosero May 2008 A1
20080132964 Cohen et al. Jun 2008 A1
20080269740 Bonde et al. Oct 2008 A1
20090012590 Inman et al. Jan 2009 A1
20090036975 Ward et al. Feb 2009 A1
20090043356 Longhini et al. Feb 2009 A1
20090048642 Goroszeniuk Feb 2009 A1
20090149912 Dacey et al. Jun 2009 A1
20090152954 Le et al. Jun 2009 A1
20090182402 Glukhovsky Jul 2009 A1
20090204170 Hastings et al. Aug 2009 A1
20090204173 Fang et al. Aug 2009 A1
20090259280 Wilkin et al. Oct 2009 A1
20090270951 Kallmyer Oct 2009 A1
20090281594 King et al. Nov 2009 A1
20090326602 Glukhovsky et al. Dec 2009 A1
20100016911 Willis et al. Jan 2010 A1
20100049289 Lund et al. Feb 2010 A1
20100094367 Sen Apr 2010 A1
20100121405 Ternes et al. May 2010 A1
20100125310 Wilson et al. May 2010 A1
20100125313 Lee et al. May 2010 A1
20100198298 Glukovsky et al. Aug 2010 A1
20100211131 Williams et al. Aug 2010 A1
20100241195 Meadows et al. Sep 2010 A1
20100249875 Kishawi et al. Sep 2010 A1
20100312320 Faltys et al. Sep 2010 A1
20100280568 Bulkes et al. Nov 2010 A1
20100305392 Gross et al. Dec 2010 A1
20100324630 Lee et al. Dec 2010 A1
20110034782 Sugimachi et al. Feb 2011 A1
20110046696 Barolat et al. Feb 2011 A1
20110087337 Forsell Apr 2011 A1
20110093036 Mashiach Apr 2011 A1
20110112605 Fahey May 2011 A1
20110137365 Ben-Erza et al. Jun 2011 A1
20110152965 Mashiach Jun 2011 A1
20110160792 Fishel Jun 2011 A1
20110160793 Gindele Jun 2011 A1
20110160798 Ackermann et al. Jun 2011 A1
20110208260 Jacobson Aug 2011 A1
20110208271 Dobak Aug 2011 A1
20110224744 Moffitt et al. Sep 2011 A1
20110224769 Spenser et al. Sep 2011 A1
20110230922 Fishel Sep 2011 A1
20110251660 Griswold Oct 2011 A1
20110270339 Murray et al. Nov 2011 A1
20110282412 Glukhovsky et al. Nov 2011 A1
20110301670 Gross Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120035679 Dagan et al. Feb 2012 A1
20120041511 Lee Feb 2012 A1
20120041514 Gross et al. Feb 2012 A1
20120065701 Cauller Mar 2012 A1
20120083857 Bradley et al. Apr 2012 A1
20120101326 Simon et al. Apr 2012 A1
20120123498 Gross May 2012 A1
20120130448 Woods et al. May 2012 A1
20120130463 Ben-David et al. May 2012 A1
20120158081 Gross et al. Jun 2012 A1
20120215285 Tahmasian et al. Aug 2012 A1
20120296389 Fang et al. Nov 2012 A1
20130006326 Ackermann et al. Jan 2013 A1
20130066393 Gross et al. Mar 2013 A1
20130192611 Taepke, II et al. Aug 2013 A1
20130325081 Karst et al. Dec 2013 A1
20130325084 Lee Dec 2013 A1
20140214134 Peterson Jul 2014 A1
20140296940 Gross Oct 2014 A1
20150004709 Nazarpoor Jan 2015 A1
20150018598 Nabutovsky et al. Jan 2015 A1
20150018728 Gross Jan 2015 A1
20150039046 Gross Feb 2015 A1
20150080979 Lasko et al. Mar 2015 A1
20150100109 Feldman et al. Apr 2015 A1
20150148861 Gross May 2015 A1
20150148878 Yoo et al. May 2015 A1
20150174406 Lamensdorf et al. Jun 2015 A1
20150258339 Burchiel et al. Sep 2015 A1
20150335882 Gross et al. Nov 2015 A1
20160206882 Oron et al. Jul 2016 A1
20160206889 Plotkin et al. Jul 2016 A1
20160206890 Oron et al. Jul 2016 A1
20160361544 Oron et al. Dec 2016 A1
20170007829 Gross Jan 2017 A1
20170119435 Gross et al. May 2017 A1
20170128724 Oron et al. May 2017 A1
20170136232 Oron et al. May 2017 A1
20170224996 Oron et al. Aug 2017 A1
20170232255 Kent et al. Aug 2017 A1
20180126157 Gross et al. May 2018 A1
20180140849 Oron et al. May 2018 A1
20190070420 Oron et al. Mar 2019 A1
20190217085 Oron et al. Jul 2019 A1
20200046974 Ostroff et al. Feb 2020 A1
Foreign Referenced Citations (36)
Number Date Country
101048194 Oct 2007 CN
101500643 Aug 2009 CN
101947357 Jan 2011 CN
203154605 Aug 2013 CN
102008054403 Jun 2010 DE
0 688 577 Dec 1995 EP
1533000 May 2005 EP
1703638 Nov 2012 EP
3167930 Feb 2020 EP
1998010832 Mar 1998 WO
1999026530 Jun 1999 WO
0110432 Feb 2001 WO
2001010375 Feb 2001 WO
0126729 Apr 2001 WO
0209808 Feb 2002 WO
2004064729 Aug 2004 WO
2006102626 Sep 2006 WO
2007019491 Feb 2007 WO
2009055574 Apr 2009 WO
2009110935 Sep 2009 WO
2011154937 Dec 2011 WO
2012012591 Jan 2012 WO
2013035092 Mar 2013 WO
2013106884 Jul 2013 WO
2013111137 Aug 2013 WO
2013156038 Oct 2013 WO
2013164829 Nov 2013 WO
2014068577 May 2014 WO
2014068577 May 2014 WO
2014081978 May 2014 WO
2014087337 Jun 2014 WO
2014167568 Oct 2014 WO
2015004673 Jan 2015 WO
2016028608 Feb 2016 WO
2016157183 Oct 2016 WO
2016172109 Oct 2016 WO
Non-Patent Literature Citations (128)
Entry
An Office Action dated Dec. 2, 2020, which issued during the prosecution of U.S. Appl. No. 16/166,383.
An Office Action dated Aug. 13, 2021, which issued during the prosecution of Chinese Patent Application No. 201610957461.7.
An Office Action dated Jun. 1, 2021, which issued during the prosecution of Chinese Patent Application No. 201610909174.9.
An Office Action dated Jun. 17, 2021, which issued during the prosecution of U.S. Appl. No. 16/363,256.
An Office Action dated May 6, 2021, which issued during the prosecution of Chinese Patent Application No. 201610957551.6.
An Office Action summarized English translation and Search Report dated May 6, 2021, which issued during the prosecution of Chinese Patent Application No. 201610957461.7.
C. de Balthasar, G. Cosendai, M. Hansen, D. Canfield, L. Chu, R. Davis, and J. Schulman, “Attachment of leads to RF-BION® microstimulators.” Jul. 2005.
D.W. Eisele, A.R. Schwartz, and P.L. Smith, “Tongue neuromuscular and direct hypoglossal nerve stimulation for obstructive sleep apnea.,” Otolaryngologic clinics of North America, vol. 36, 2003, p. 501.
G.E. Loeb, F.J.R. Richmond, J. Singh, R.A. Peck, W. Tan, Q. Zou, and N. Sachs, “RF-powered BIONs™ for stimulation and sensing,” Engineering in Medicine and Biology Society, 2004. IEMBS'04. 26th Annual International Conference of the IEEE, 2005, pp. 4182-4185.
G.E. Loeb, F.J. Richmond, and L.L. Baker, “The BION devices: injectable interfaces with peripheral nerves and muscles,” Neurosurgical focus, vol. 20, 2006, pp. 1-9.
E.A. Mann, T. Burnett, S. Cornell, and C.L. Ludlow, “The effect of neuromuscular stimulation of the genioglossus on the hypopharyngeal airway,” The Laryngoscope, vol. 112, 2002, pp. 351-356.
A. Oliven, R.P. Schnall, G. Pillar, N. Gavriely, and M. Odeh, “Sublingual electrical stimulation of the tongue during wakefulness and sleep,” Respiration physiology, vol. 127, 2001, pp. 217-226.
A. Oliven, D.J. O'Hearn, A. Boudewyns, M. Odeh, W. De Backer, P. van de Heyning, P.L. Smith, D.W. Eisele, L. Allan, H. Schneider, and others, “Upper airway response to electrical stimulation of the genioglossus in obstructive sleep apnea,” Journal of Applied Physiology, vol. 95, 2003, p. 2023.
A. Oliven, M. Odeh, L. Geitini, R. Oliven, U. Steinfeld, A.R. Schwartz, and N. Tov, “Effect of coactivation of tongue protrusor and retractor muscles on pharyngeal lumen and airflow in sleep apnea patients,” Journal of Applied Physiology, vol. 103, 2007, p. 1662.
A.R. Schwartz, D.W. Eisele, A. Hari, R. Testerman, D. Erickson, and P.L. Smith, “Electrical stimulation of the lingual musculature in obstructive sleep apnea,” Journal of Applied Physiology, vol. 81, 1996, p. 643.
W.H. Tran, G.E. Loeb, F.J.R. Richmond, A.C. Dupont, K.C. Mahutte, C.S.H. Sassoon, and M.J. Dickel, “Development of asynchronous, intralingual electrical stimulation to treat obstructive sleep apnea,” Engineering in Medicine and Biology Society, 2003. Proceedings of the 25th Annual International Conference of the IEEE, 2004, pp. 375-378.
W.H. Tran, G.E. Loeb, F.J.R. Richmond, R. Ahmed, G.T. Clark, and P.B. Haberman, “First subject evaluated with simulated BION™ treatment in genioglossus to prevent obstructive sleep apnea,” Engineering in Medicine and Biology Society, 2004. IEMBS'04. 26th Annual International Conference of the IEEE, 2005, pp. 4287-4289.
P.R. Troyk, “Injectable electronic identification, monitoring, and stimulation systems,” Biomedical Engineering, vol. 1, 1999, p. 177.
T.K. Whitehurst, J.H. Schulman, K.N. Jaax, and R. Carbunaru, “The Bion® Microstimulator and its Clinical Applications,” Implantable Neural Prostheses 1, 2009, pp. 253-273.
D.J. Young, “Wireless powering and data telemetry for biomedical implants,” Engineering in Medicine and Biology Society, 2009. EMBC 2009. Annual International Conference of the IEEE, 2009, pp. 3221-3224.
Reid R. Harrison, et al., “Wireless Neural Recording with Single Low-Power Integrated Circuit”, IEEE Trans Neural Syst Rehabil Eng. Aug. 2009; 17(4):322-329.
An International Search Report and a Written Opinion both dated Apr. 17, 2012 which issued during the prosecution of Applicant's PCT/IL11/00870.
Patents Galore: Implantable Neurostimulators Fight Snoring and Corpse Eye-Proof Scanners. Printout from http://medgadget.com/2006/03/patents_galore.html (Downloaded Jan. 2012).
Chris Seper, “Neuros Medical Launches to Develop New Device to Block Amputee, Chronic Pain”, Mar. 17, 2009.
Urgent® PC, Simple. Safe. Effective. Neuromodulation System, Uroplasty, Mar. 2009.
“JumpStart and Case Technology Ventures Invest in Neuros Medical”, CTV Case Technology Ventures, Mar. 17, 2009.
“Responses to median and tibial nerve stimulation in patients with chronic neuropathic pain”, by Theuvenet, Brain Topography, vol. 11, No. 4, 1999, pp. 305-313(9)—an abstract.
Armstrong, J, “Is electrical stimulation effective in reducing neuropathic pain in patients with diabetes?”, by Foot Ankle Surg. Jul.-Aug. 1997; 36(4): 260-3—an abstract.
Ross Davis, Cerebellar Stimulation for Cerebral Palsy Spasticity, Function and Seizures. Clinical Neuroscience Center, 1999. pp. 290-299.
An Office Action dated Feb. 13, 2004, which issued during the prosecution of U.S. Appl. No. 10/254,024.
Bathien et al., Inhibition and synchronisation of tremor induced by a muscle twitch. J. Neurol, Neurosurg. And Psych. 1980, 43, 713-718.
Jobges et al., Vibratory proprioceptive stimulation affects Parkinsonian tremor. Parkinsonism & Related Disorders, 8(3), 171-176, Jan. 2002.
Mones and Weiss, The response of the tremor of patients with Parkinsonism to peripheral nerve stimulation. J. Neurol. Neurosurg. Psychiat. 1969, 32. 512-519.
Y. Zhang, et al., “Optimal Ventricular Rate Slowing During Atrial Fibrillation by Feedback AV Nodal-Selective Vagal Stimulation”, Am J Physiol Heart Circ Physiol 282:H1102-H1110, 2002.
N.J.M. Rijkhoff, et al., “Selective Stimulation of Small Diameter Nerve Fibers in a Mixed Bundle”, Proceedings of the Annual Project Meeting Sensations/Neuros and Mid Term Review Meeting Neuros, Apr. 21-23, 1999.
M. Manfredi, “Differential Block of conduction of larger fibers in peripheral nerve by direct current”, Arch. Ital. Biol. 108:52-71, 1970.
A Restriction Requirement dated May 11, 2012, which issued during the prosecution of U.S. Appl. No. 12/946,246.
Cerebral Palsy, Barry S. Russman MD, CCurrent Science Inc. 2000.
A Notice of Allowance dated Mar. 7, 2005, which issued during the prosecution of U.S. Appl. No. 10/254,024.
A Notice of Allowance dated Aug. 26, 2004, which issued during the prosecution of U.S. Appl. No. 10/254,024.
An Office Action dated Jun. 24, 2011, which issued during the prosecution of U.S. Appl. No. 12/796,102.
An International Search Report and a Written Opinion both dated Nov. 14, 2011, which issued during the prosecution of Applicant's PCT/IL2011/000440.
An International Preliminary Report on Patentability dated Dec. 10, 2012, which issued during the prosecution of Applicant's PCT/IL2011/000440.
U.S. Appl. No. 60/263,834, filed Jan. 2, 2001.
Sweeney JD et al., “An asymmetric two electrode cuff for generation of unidirectionally propagated action potentials,” IEEE Transactions on Biomedical Engineering, vol. BME-33(6) (1986).
An Office Action dated Apr. 9, 2012, which issued during the prosecution of U.S. Appl. No. 12/796,102.
Invitation to pay Additional Fees dated May 10, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050069.
Naples GG et al., “A spiral nerve cuff electrode for peripheral nerve stimulation,” by IEEE Transactions on Biomedical Engineering, 35(11) (1988).
Sweeney JD et al., “A nerve cuff technique for selective excitation of peripheral nerve trunk regions,” IEEE Transactions on Biomedical Engineering, 37(7) (1990).
Ungar IJ et al., “Generation of unidirectionally propagating action potentials using a monopolar electrode cuff,” Annals of Biomedical Engineering, 14:437-450 (1986).
Fitzpatrick et al., in “A nerve cuff design for the selective activation and blocking of myelinated nerve fibers,” Ann. Conf. of the IEEE Eng. in Medicine and Biology Soc, 13(2), 906 (1991).
Rijkhoff NJ et al., “Orderly recruitment of motoneurons in an acute rabbit model,” Ann. Conf. of the IEEE Eng., Medicine and Biology Soc., 20(5):2564 (1998).
Van den Honert C et al., “A technique for collision block of peripheral nerve: Frequency dependence,” MP-12, IEEE Trans. Biomed. Eng. 28:379-382 (1981).
Baratta R et al., “Orderly stimulation of skeletal muscle motor units with tripolar nerve cuff electrode,” IEEE Transactions on Biomedical Engineering, 36(8):836-43 (1989).
Van den Honert C et al., “Generation of unidirectionally propagated action potentials in a peripheral nerve by brief stimuli,” Science, 206:1311-1312 (1979).
M. Devor, “Pain Networks”, Handbook of Brand Theory and Neural Networks, ED M.A. Arbib MIT Press pp. 696-701, 1998.
Epilepsy center. http://www.bcm.tmc.edu/neural/struct/epilep/epilpsy_vagus.html.
J.F. Cortese, “Vagus Nerve Stimulation for Control of Intractable Epileptic Seizures”, May 31, 2001.
Evetovich T.K. et al., Gender comparisons of the mechanomyographic responses to minimal concentric and eccentric isokinetic muscle actions, Medicine & Science in Sports & Exercise, 1998 pp. 1697-1702. Abstract.
An Office Action dated Dec. 5, 2013, which issued during the prosecution of U.S. Appl. No. 13/528,433.
An Office Action dated Sep. 30, 2013, which issued during the prosecution of U.S. Appl. No. 12/796,102.
Chow et al., Evaluation of Cardiovascular Stents as Antennas for Implantable Wireless Applications, IEEE Transactions on Microwave Theory and Techniques, vol. 57, No. 10, Oct. 2009.
Dean, J. et al., “Motor Pattern Generation”, Handbook of Brain Theory and Neural Networks, pp. 696-701.
Hu et al., Percutaneous Biphasic Electrical Stimulation for Treatment of Obstructive Sleep Apnea Syndrome, IEEE Transactions on Biomedical Engineering, Jan. 2008 vol. 55 Issue:1 p. 181-187—an abstract.
A. Oliven, Electrical stimulation of the genioglossus to improve pharyngeal patency in obstructive sleep apnea: comparison of resultsobtained during sleep and anesthesia, U.S. National Library of Medicine, National Institutes of Health May 2009;148(5):315-9, 350, 349—an abstract.
Mortimer et al., Peripheral Nerve and Muscle Stimulation, Neuroprosthetics Theory and Practice, Chapter 4.2, 2004, p. 632-638.
An Office Action dated May 19, 2017, which issued during the prosecution of U.S. Appl. No. 14/935,941.
Zabara J., Inhibition of experimental seizures in canines by repetitive vagal stimulation, Epilepsia. Nov.-Dec. 1992;33 (6):1005-12, http://www.ncbi.nlm.nih.gov/pubmed/1464256—an abstract.
A Notice of Allowance dated Jun. 9, 2014, which issued during the prosecution of U.S. Appl. No. 12/796,102.
Notice of Allowance dated Sep. 1, 2017, which issued during the prosecution of U.S. Appl. No. 14/649,873.
Brindley (1983) A technique for modally blocking large nerve fibers.
An Office Action dated Sep. 22, 2016, which issued during the prosecution of U.S. Appl. No. 14/374,375.
DJOGlobal.com—Interferential Current Therapy (IFC).
A Notice of Allowance dated Apr. 25, 2014, which issued during the prosecution of U.S. Appl. No. 13/528,433.
An Office Action dated Sep. 26, 2013, which issued during the prosecution of U.S. Appl. No. 13/528,433.
U.S. Appl. No. 60/985,353, filed Nov. 5, 2007.
An Office Action dated Apr. 4, 2017, which issued during the prosecution of U.S. Appl. No. 14/601,604.
electrotherapy.org—Interferential Therapy.
An Office Action dated Feb. 27, 2017, which issued during the prosecution of U.S. Appl. No. 14/649,873.
Lind (2012) Advances in spinal cord stimulation.
Physical Therapy Web.com—Interferential Current (IFC) Equipment.
Shealy (1967) Electrical inhibition of pain by stimulation of the dorsal columns.
Nov. 30, 2015 massdevice.com—St. Jude Medical's Proclaim Elite debuts in Europe.
Kaplan et al. (2009) Design and fabrication of an injection tool for neuromuscular microstimulators.
Supplementary European during the prosecution of Search Report dated Dec. 22, 2014, which issued during the prosecution of Applicant's European App No. 11792044.7.
An Office Action dated Oct. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/226,723.
Notice of Allowance dated Jun. 15, 2017, which issued during the prosecution of U.S. Appl. No. 14/939,418.
Sinan Filiz, Luke Xie, Lee E. Weiss, O.B. Ozdoganlar, Micromilling of microbarbs for medical implants, International Journal of Machine Tools and Manufacture, vol. 48, Issues 3-4, Mar. 2008, pp. 459-472.
UCLA Team Reports Initial Success with Trigeminal Nerve Stimulation epilepsy. https://web.archive.org/web/20121020145122/https:/www.epilepsy.com/epilepsy/newsletter/apr09_STIM.
Kucklick, Theodore R., ed. The medical device R&D handbook. Chapter 3—Intro to needles and cannulae. CRC Press, 2012.
Szmurlo, R., Starzynski, J., Wincenciak, S. and Rysz, A. (2009) ‘Numerical model of vagus nerve electrical stimulation’, COMPEL—The international journal for computation and mathematics in electrical and electronic engineering, 28(1), pp. 211-220.
An Office Action dated Apr. 5, 2017, which issued during the prosecution of U.S. Appl. No. 14/374,375.
Mitchum, A Shocking Improvement in Cardiology Science Life Blog, University of Chicago, http://sciencelife.uchospitals.edu/2010/04/13/a-shocking-improvement-in-cardiology/ (Downloaded Nov. 3, 2012).
Reggiani et al. “Biophysical effects of high frequency electrical field on muscle fibers in culture.” (2009) pp. 49-56.
An Office Action dated Aug. 8, 2016, which issued during the prosecution of U.S. Appl. No. 14/735,741.
An International Search Report and a Written Opinion both dated Jul. 11, 2013, which issued during the rosecution of Applicant's PCT/IL2013/050069.
An International Search Report and a Written Opinion both dated Apr. 29, 2014, whichissued during the prosecution of Applicant's PCT/IB2013/060607.
An International Preliminary Report on Patentability dated Jul. 29, 2014, which issued during the prosecution of Applicant's PCT/IL2013/050069.
An International Preliminary Report on Patentability dated Jun. 9, 2015, which issued during the prosecution of Applicant's PCT/IB2013/060607.
An Office Action dated Dec. 12, 2016, which issued during the prosecution of U.S. Appl. No. 14/939,418.
Notice of Allowance dated Mar. 22, 2017, which issued during the prosecution of U.S. Appl. No. 14/939,418.
Injecta 2013 GmbH catalogue.
An Office Action dated Feb. 13, 2017, which issued during the prosecution of U.S. Appl. No. 14/601,604.
U.S. Appl. No. 61/733,995, filed Dec. 6, 2012.
Alo, Kenneth M., et al. “Lumbar and sacral nerve root stimulation (NRS) in the treatment of chronic pain: a novel anatomic approach and neuro stimulation technique.” Neuromudulation: Technology at the Neural Interface 2.1 (1999): 23-31.
European Search Report dated Mar. 10, 2017, which issued during the prosecution of Applicant's European App No. 16196864.9.
An Office Action dated Nov. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/601,626.
Stuart, R. Morgan, and Christopher J. Winfree. “Neurostimulation techniques for painful peripheral nerve disorders.” Neurosurgery Clinics of North America 20.1 (2009): 111-120.
European Search Report dated Feb. 3, 2017, which issued during the prosecution of Applicant's European App No. 16196878.9.
Gofeld, Michael, and John G. Hanlon. “Ultrasound-Guided Placement of a Paddle Lead Onto Peripheral Nerves: Surgical Anatomy and Methodology.” Neuromodulation: Technology at the Neural Interface 17.1 (2014): 48-53.
An Office Action dated Dec. 6, 2017, which issued during the prosecution of U.S. Appl. No. 14/601,604.
An Office Action dated Dec. 26, 2017, which issued during the prosecution of U.S. Appl. No. 14/935,941.
An Office Action dated Jan. 8, 2018, which issued during the prosecution of U.S. Appl. No. 14/935,941.
An Office Action dated Mar. 5, 2018, which issued during the prosecution of U.S. Appl. No. 15/360,501.
An Office Action dated Nov. 30, 2017, which issued during the prosecution of U.S. Appl. No. 15/726,971.
A Notice of Allowance dated Feb. 15, 2018, which issued during the prosecution of U.S. Appl. No. 14/601,604.
A Notice of Allowance dated Jul. 16, 2018, which issued during the prosecution of U.S. Appl. No. 15/360,501.
An Office Action dated Jun. 4, 2018, which issued during the prosecution of U.S. Appl. No. 15/860,385.
Notice of Allowance dated Oct. 22, 2018, which issued during the prosecution of U.S. Appl. No. 15/860,385.
An Office Action dated Jun. 26, 2019, which issued during the prosecution of U.S. Appl. No. 15/395,257.
An Office Action dated Dec. 5, 2018, which issued during the prosecution of U.S. Appl. No. 15/581,390.
An Office Action dated Feb. 7, 2019, which issued during the prosecution of U.S. Appl. No. 15/706,956.
An Office Action dated Jul. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/363,256.
An Office Action dated Apr. 22, 2019, which issued during the prosecution of U.S. Appl. No. 15/638,924.
Notice of Allowance dated Jun. 17, 2019, which issued during the prosecution of U.S. Appl. No. 15/581,390.
Notice of Allowance dated May 20, 2020, which issued during the prosecution of U.S. Appl. No. 16/183,783.
An Interview Summary dated Sep. 6, 2018, which issued during the prosecution of U.S. Appl. No. 15/860,385.
An Office Action dated Dec. 21, 2020, which issued during the prosecution of U.S. Appl. No. 16/363,256.
Related Publications (1)
Number Date Country
20200346020 A1 Nov 2020 US
Continuations (2)
Number Date Country
Parent 16183783 Nov 2018 US
Child 16934692 US
Parent 15360501 Nov 2016 US
Child 16183783 US